Neos Therapeutics, Inc. (NEOS) is a commercial-stage pharma company that uses a unique delivery mechanism to deliver treatments in the ADHD space. The company has 3 approved products:
- Adzenys XR-ODT® (amphetamine), an extended-release orally disintegrating tablet.
- Cotempla XR-ODT® (methylphenidate), also an extended-release orally disintegrating tablet.
- Adzenys-ER®(amphetamine), an extended-release oral suspension.
With losses mounting and substantial debt repayments ahead of it, NEOS made a strategic decision to shift to more profitable business channels and market segmentation so that it could essentially ditch those channels that weren't making enough for them and double